SCHEMBL13311367

SCHEMBL13311367

CCCN1C(=O)C2C(C1=O)[C@H]1CC[C@@H]2O1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
PPM1B O75688 3/20 0.42
LMNA P02545 2/20 0.42
RAB9A P51151 2/20 0.42
KDM4E B2RXH2 2/20 0.42
GMNN O75496 1/20 0.42
PPP1CC P36873 1/20 0.42
TFPI2 P48307 1/20 0.42
PPP5C P53041 1/20 0.42
PPP1CA P62136 1/20 0.42
PMP22 Q01453 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
TP53 P04637 1/20 0.42
CYP2D6 P10635 1/20 0.42
NFKB1 P19838 1/20 0.42
THPO P40225 1/20 0.42
CYP19A1 P11511 3/20 0.37
CNR2 P34972 3/20 0.36
CNR1 P21554 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3495026 1.00 L3MBTL1 (0.42) L3MBTL1SMN1; SMN2PPM1BLMNARAB9A
SCHEMBL3494259 0.89 SMN1; SMN2 (0.51) L3MBTL1SMN1; SMN2PPM1BLMNARAB9A
SCHEMBL17532429 0.88 PPM1B (0.48) L3MBTL1SMN1; SMN2PPM1BLMNARAB9A
SCHEMBL3496388 0.86 CNR2 (0.53) SMN1; SMN2RAB9ACYP19A1CNR2CNR1
SCHEMBL3495647 0.86 CNR2 (0.53) SMN1; SMN2RAB9ACYP19A1CNR2CNR1
SCHEMBL14344341 0.84 PPM1B (0.45) L3MBTL1SMN1; SMN2PPM1BLMNARAB9A
SCHEMBL13311489 0.84 ALDH1A1 (0.46) L3MBTL1SMN1; SMN2PPM1BLMNARAB9A
SCHEMBL17532421 0.84 ALDH1A1 (0.46) L3MBTL1SMN1; SMN2PPM1BLMNARAB9A
SCHEMBL17532425 0.82 RAB9A (0.52) L3MBTL1SMN1; SMN2PPM1BLMNARAB9A
SCHEMBL13311393 0.81 PPM1B (0.43) L3MBTL1SMN1; SMN2PPM1BLMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137294-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS GENETIC TECHNOLOGIES LIMITED (AU) 2010-06-03 US disclosed
US-20100137294-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS GENETIC TECHNOLOGIES LIMITED (AU) 2010-06-03 US disclosed
WO-2008058342-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS GENETIC TECHNOLOGIES LIMITED (AU) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137294-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS PPP1R10, TASP1, PPP5C L3MBTL1 598/4885SMN1; SMN2 3065/4885PPM1B 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.